QULIPTA (AbbVie)
(https://qulipta.com) 📸 Data Snapshot: June 19, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Authority is well-established through AbbVie’s corporate identity and proper schema_json implementation. The use of MedicalWebPage and Drug schema with sameAs links to Wikipedia for Atogepant provides a verifiable digital footprint. The only minor gap is the reliance on a single named patient (Kelsi) without a professional digital footprint for other ‘experts’ beyond the corporate entity.
There is a minor disconnect between the emotional marketing claim of ‘forgetting’ you have migraines and the clinical data which merely shows a reduction in migraine days. However, the site uses mandatory qualifiers like ‘Individual results may vary’ and ‘You will never truly forget migraine’ to bridge the gap between marketing tone and medical reality.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
[
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.qulipta.com/",
"name": "QULIPTA® (atogepant) for Migraine Prevention",
"description": "Discover QULIPTA® (atogepant), a pill specifically designed to prevent migraine attacks in adults. See full Patient and Safety Information.",
"audience": {
"@type": "MedicalAudience",
"audiencetype": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Migraine.",
"description": "Migraine is a neurological condition characterized by recurrent headaches that can be moderate to severe in intensity. Migraine headaches are often accompanied by other symptoms such as sensitivity to light, sound, or smells, nausea, and vomiting. Migraines can be triggered by various factors such as stress, certain foods, hormonal changes, and environmental factors."
}
},
"mainEntity": {
"@type": "Drug",
"name": "QULIPTA",
"description": "QULIPTA is a once-daily pill that blocks CGRP and is approved to prevent migraine of any frequency.",
"activeIngredient": "Atogepant.",
"sameAs": "https://en.wikipedia.org/wiki/Atogepant",
"warning": "QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you have kidney problems or are pregnant or plan to become pregnant.",
"manufacturer": {
"@type": "Organization",
"name": "AbbVie",
"brand": "QULIPTA",
"url": "https://www.abbvie.com",
"description": "AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines in various therapeutic areas, including immunology, oncology, neuroscience, and virology."
},
"prescribingInfo": "https://www.rxabbvie.com/pdf/qulipta_pil.pdf"
}
}
]
/why-qulipta/
[
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"url": "https://www.qulipta.com/why-qulipta",
"name": "What Is QULIPTA® (atogepant)? - A Migraine Preventive Treatment",
"description": "Learn about QULIPTA® (atogepant), a pill that can help prevent migraine attacks in adults and keep them away over time. See full Patient & Safety Info.",
"audience": {
"@type": "MedicalAudience",
"audiencetype": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Migraine",
"description": "Migraine is a neurological condition characterized by intense, debilitating headaches."
}
},
"specialty": {
"@type": "MedicalSpecialty",
"@context": "https://schema.org",
"name": "Neurologic"
},
"mainEntity": {
"@context": "https://schema.org/",
"@type": "Drug",
"name": "QULIPTA",
"description": "QULIPTA is a once-daily pill that blocks CGRP and is approved to prevent migraine of any frequency.",
"activeIngredient": "Atogepant.",
"sameAs": "https://en.wikipedia.org/wiki/Atogepant",
"drugUnit": "mg",
"dosageForm": "Pill",
"mechanismOfAction": "QULIPTA (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the activity of CGRP, a protein that is involved in the development of migraines. By blocking CGRP, QULIPTA helps to prevent migraines from occurring.",
"warning": "Do not take QULIPTA if you have had an allergic reaction to atogepant or any ingredients in QULIPTA. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you have kidney problems or are on dialysis, or if you are pregnant or plan to become pregnant. Stop taking QULIPTA and get emergency medical help right away if you get any of the following symptoms, which may be part of a serious allergic reaction: swelling of the face, lips, or tongue; itching; trouble breathing; hives; or rash.",
"doseSchedule": {
"@type": "DoseSchedule",
"doseValue": [
"10",
"30",
"60"
],
"frequency": "Once daily",
"description": "Take one pill daily"
},
"drugClass": "Calcitonin gene-related peptide (CGRP) receptor antagonist.",
"manufacturer": {
"@type": "Organization",
"name": "AbbVie",
"brand": "QULIPTA",
"url": "https://www.abbvie.com",
"description": "AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines in various therapeutic areas, including immunology, oncology, neuroscience, and virology."
},
"prescribingInfo": "https://www.rxabbvie.com/pdf/qulipta_pil.pdf"
}
}
]
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 2 |
| /why-qulipta/ | 0 | 2 |
| /savings-support/qulipta-complete-savings-program/ | 2 | 2 |
| /savings-support/qulipta-complete-savings-program/sign-up/ | 0 | 2 |
This page presents a snapshot of public data from QULIPTA (AbbVie), captured on June 19, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to QULIPTA (AbbVie): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://qulipta.com to view the most current version of its content and see directly what this company is about and what it offers.